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Frailty in Parkinson’s disease: A systematic review 
 
Abstract 
Background: Parkinson’s disease (PD) and frailty are two conditions that are increasingly 
common with advancing age, yet little is known about their relationship.  
Objective: The aim of this study was to examine the co-occurrence of frailty in people with PD; 
to describe the measures used to assess frailty in PD, and assess the prevalence of frailty in 
subjects with PD. 
Methods: We conducted a systematic review of Pubmed and Embase in April 2018. Studies that 
assessed frailty in subjects with PD were included in the review and data was extracted on the 
prevalence of frailty in subjects with PD. Due to heterogeneity of studies a meta-analysis was 
not performed. 
Results: 8 studies were included in the review, of which 7 were cross-sectional and 1 a 
prospective cohort study. Mean age of participants with PD in the studies ranged from 66 to 85 
years. The majority (6/8) used the 5-item, Fried criteria to measure frailty, with the remainder 
using index-based measures. 5 studies provided data on the prevalence of frailty in PD, which 
ranged from 29% to 67%.  
Conclusions: Few studies have quantified the prevalence of frailty in PD, but those that have 
suggest a high concurrence of these two conditions. 
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Background  
 
Parkinson’s disease (PD) and frailty are both highly prevalent in older people.  Despite the 
frequency with which both conditions are encountered in clinical practice, the coexistence, 
overlap and potential interaction between the two states has not been fully explored.  The 
topic of frailty remains complex, not least as the term ‘frailty’ is ambiguous and has eluded a 
consensus definition [1].  
Frailty is recognised as a state of increased vulnerability and loss of resilience to stressors [2], 
which, in turn, confers an increased risk of disability and death. A combination of inflammatory, 
hormonal, and nutritional changes are associated with frailty, and have been suggested as key 
factors in its pathogenesis, although more research is needed to confirm a causal link [3]. The 
manifestation of frailty is such that a critical tipping point exists whereby reserve has been 
diminished to such an extent that an individual cannot adapt to physiological change and 
homeostatic balance is disrupted. Physical frailty is also known to be related to cognitive 
impairment, leading to the recently defined condition of “cognitive frailty” [4].   
The operationalisation of the frailty concept varies, but two principal approaches have been 
adopted for use in clinical studies. Firstly, a clinical phenotypic model, first proposed by Fried 
[5] suggested that an individual is frail in the presence of three or more of five criteria; 
weakness, weight loss, slow walking speed, fatigue, and low physical activity.  Conversely, an 
alternative index-based approach was first described by Rockwood and Mitniski [6], whereby 
the accumulation of multiple deficits of symptoms, disability and disease, contribute to an 
overall burden of frailty.  
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Advancing age coupled with PD are not inevitable antecedents of frailty. Albeit less commonly, 
frailty can be encountered in the absence of overt comorbidities. However, the impact of both 
non-motor and motor symptoms in PD may well ‘fuel’ a frailty syndrome, whereby the 
combination of factors confers an accelerated and augmented risk of negative outcomes. 
Factors such as fatigue, gait and balance impairment, cognitive changes, polypharmacy and 
adverse drug reactions all contribute to functional impairment when carrying out activities of 
daily living, and these feature almost invariably in older frail adults. 
The objective of this study was to systematically review the literature to a) describe studies that 
have examined frailty in people with Parkinson’s disease, b) describe the current measures 
used to assess frailty in PD and c) determine the prevalence of frailty in PD.   
 
Methods 
 
Search strategy and selection criteria 
 
This systematic review was designed and reported within the PRISMA framework – the study 
protocol was not published, but is available on request. A systematic search of Medline 
(Pubmed) and Embase was performed from the start of the database to 4th April 2018, and was 
conducted in line with the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
criteria. The search strategy included MeSH Terms and keyword variations (see Appendix 1 for 
full search strategies), to identify all studies investigating frailty in patients with PD. The 
following strategy was used in the Pubmed database: ("parkinson disease"[MeSH] OR 
"parkinsonian disorders"[MeSH] OR parkinson*[tw]) AND frail*[tw]. The search was limited to 
English-language publications.  
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Studies were included if they satisfied the following criteria:  
a) population: enrolled subjects with a diagnosis of PD. Populations with patients with 
parkinsonian symptoms, but without formal PD diagnoses were excluded. 
b) outcome: measured frailty, assessed using a formal operationalised measure, such as the 
Fried criteria or Rockwood frailty index. Studies that defined frailty according to a measure of 
functional impairment (e.g. the ability to perform activities of daily living) or in a non-objective, 
non-standardised manner, were excluded. 
Reviews, editorials, case studies and conference abstracts were excluded. Two reviewers (N.S., 
L.B.) evaluated each abstract for inclusion according to these criteria, and of selected abstracts, 
full publications were then obtained and reviewed in detail by the same two independent 
reviewers. 
 
 
Data extraction and quality assessment 
After inclusion, the following information was extracted from each study to a data extraction 
form: study date, sample size, demographic characteristics of subjects, number of people in the 
sample with PD, the frailty measure used and findings regarding frailty (principle measure being 
frailty prevalence). Study authors were contacted when required to provide further 
information.  
The methodological quality of included studies was judged based on an adapted version of the 
Newcastle – Ottawa Scale [7] (NOS). This rating scale was developed to assess the quality of 
non-randomised studies in meta-analyses, and scores studies based on 3 domains: on the 
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selection of the study sample; the comparability of groups and control of confounding factors; 
and outcome measurement. We assigned studies up to a maximum of 8 points based on this 
scoring system. The original NOS was developed for use with case-control and cohort studies, 
we adapted it to also apply it to cross-sectional studies, in line with previous research [8, 9].  
In the case of multiple studies drawing on the same cohort, data was drawn from the study that 
included the largest number of participants, and had the best NOS score. Two authors (N.S., 
L.B.) independently extracted the data, and scored the studies quality. Any differences were 
resolved by discussion, and referred to a third researcher (E.H.) when required.   
 
Data synthesis 
 
Due to heterogeneity of the studies – including differences in population, frailty measure used 
and study design – a meta-analysis was not performed on the outcome of frailty prevalence in 
PD. Results of our data extraction were instead synthesised in tabular, graphical and narrative 
form.  
 
Results  
 
The search yielded 116 articles in PubMed, and 241 in EMBASE. Reference lists of included 
studies were handsearched for any further studies, which yielded 1 additional article. The initial 
literature search therefore yielded 358 results and after removing duplicates, 256 remained. Of 
these, 230 were excluded at the initial screening of abstracts, and 17 more were discarded after 
detailed review, for failing to meet the inclusion criteria (see Fig 1 for PRISMA flowchart). One 
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further paper was excluded at a later stage after authors were unable to provide data for PD 
subjects [18]. 8 papers remained for data extraction (see Table 1) [10-17].  
 
 
  
Excluded: No data 
provided for PD 
subjects (n=1) 
 
Records excluded (n = 230) 
 
Editorial (2) 
Review (9) 
Case Report (8) 
Conference abstract (31) 
Not relevant (131) 
No frailty assessment (35) 
No PD subjects (14) 
 
Full-text articles 
assessed for eligibility  
(n =  26 ) 
Records excluded (n = 17) 
No frailty assessment (9) 
No PD subjects (8) 
 
Studies included in 
qualitative synthesis  
(n = 8 ) 
Records identified through 
database searching  
(n =  357 ) 
Additional records identified 
through other sources  
(n =  1 ) 
Records after duplicates removed  
(n = 256 ) 
Records screened  
(n = 256 ) 
PRISMA 2009 Flow Diagram: Literature 
search 
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Of the 8 papers analysed, 7 were cross-sectional studies [10-16], and 1 a prospective cohort 
study [17].  
Correspondence with authors revealed that the same cohort of PD participants was used for 
four of the cross-sectional studies [10-13]. These studies were assessed separately and all 
included in the descriptive review, but data for frailty estimates was only extracted from one 
[13].  
The authors of one large prospective cohort study [17] provided further unpublished data. In 
view of the different study design we utilised the last available frailty status of the participants 
to calculate the cumulative risk of frailty over time. We are aware that these risks therefore 
does not constitute a “true” prevalence figure, and therefore chose to present them separately 
to the data from the cross-sectional papers. 
 
Methodological quality 
 
The detail of the methodology in the extracted papers varied, and was often limited. Seven of 
the 8 studies scored moderately on the NOS, with only one paper scoring less than 4 (see Table 
1). The studies were weakest in their sample selection, with 6 of the 8 papers scoring only 1 or 
2 points in this domain (out of a possible 4). This was generally due to studies having small 
samples that were often not representative of the average PD patient, with samples ranging 
from 13 up to 74 subjects. Few studies justified their sample size, and many omitted 
information on response rate or non-responders. The studies performed better on 
comparability and outcome – only 2 studies did not control for key factors when analysing 
outcomes, and 7 out of 8 papers scored full marks on the assessment of frailty. Of the 5 studies 
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from which frailty data was extracted, overall NOS scores ranged from 4 to 8, with an average 
score of 5.8 (see Appendix 2 for full breakdown of scores).  
 
Population 
 
The majority (7/8) of the studies sampled patients from the general population, as opposed to a 
clinical cohort from e.g. a secondary care population. Three cross-sectional studies exclusively 
recruited patients with PD [10, 12, 14] and two recruited PD patients as well as matched 
controls [11, 13]. The prospective cohort study included up to 74 people with PD, from having 
sampled a large cohorts of older people [17]. PD participants were sampled throughout the 
course of their disease, from those living independently in the community [10-16], to those 
with more advanced disease and comorbidity, including some residing in institutions [17].  
 
Classification of frailty   
 
Most of the studies used the Fried frailty criteria [10-14] or a variation thereof [17] as a 
measure of frailty. The five criteria included were weight loss of >10lbs in the past year, 
maximal hand-grip strength, time to walk 15 feet at usual pace, self-reported inactivity, and 
self-reported exhaustion [10-14]. 1 point is scored for each positive feature. Consequently 
patients were stratified as non-frail (score 0), pre-frail (score 1-2 ) or frail (score ≥3). Most of the 
papers [11, 13, 14] operationalised self-reported exhaustion by using two questions from the 
Center for Epidemiologic Studies Depression Scale (CES-D). Self-reported activity was quantified 
in kcals using the Minnesota Leisure Time Activities Questionnaire (MLTA), as per the original 
criteria [13] or this was modified and an exercise log was completed [14]. One paper [17] used a 
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modified version of the Fried criteria summarising the four components of grip strength, 8 feet 
timed walk, BMI and fatigue (CES-D) in a composite measure.  
 
Two studies [15, 16] utilised index-based approaches to measure frailty according to the 
accumulation of deficits. Both used questionnaires to gather responses on physical, mental and 
social domains – one using the Functional Geriatric Evaluation questionnaire (FGE) [15], and the 
other part of the Tilburg Frailty Indicator (TFI) [16]. These assessments were used to calculate 
overall scores, from which frailty categories were derived. 
 
Prevalence of frailty in PD 
 
Five studies provided data for the number of frail people in a group of PD subjects [13-17]. 
There was some evidence for heterogeneity of the prevalence estimates (I2=63%, p=0.04) and 
these ranged from 29% to 67%, shown as a Forest Plot in Figure 2. The wide range of these 
estimates is likely partly due to the different frailty measures employed. The three studies that 
used the Fried criteria described a frailty prevalence of 29%-33% in PD subjects, whereas the 
estimate was higher in the studies utilising index-based measures (50% to 67%). 
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Predictors of frailty status   
 
Four studies examined individual components of the 5 Fried frailty criteria, to assess which 
factors were best able to differentiate between frail and non-frail PD subjects. Studies were 
contradictory in respect to whether or not activity levels were associated with frailty status.  
Two of the studies papers [10, 11] found that neither self-reported activity nor objectively 
measured physical activity were related to overall frailty in the PD participants, in contrast to 
findings from non-PD cohorts. However, Roland et al. identified self-reported exhaustion as a 
strong predictor of frailty in PD subjects in one small study (R2=0.44) [12].  
 
Forest plot for prevalence of frailty 
in subjects with PD 
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In contrast, Ahmed et al. [14] examined the five Fried criteria and found activity (measured as 
weekly calorific expenditure) to be the best discriminator between frail and non-frail PD 
subjects (OR 22; p<0.001). Of the remaining Fried criteria, grip strength, walk time and 
exhaustion were all also significantly associated with frailty status, with only weight loss 
forming an exception. Ahmed et al. also examined the factors as continuous variables, noting 
that grip strength no longer differed between frail and non-frail, whereas walking time was 
significantly lower in the frail group (p<0.001).  
 
Frailty and PD severity 
 
Five studies reported that higher frailty scores (using the Fried model) were associated with 
markers of disease severity in PD subjects. Three studies by Roland et al. described that those 
that were frail took higher doses of dopaminergic drugs [10], with two [11, 13] reporting that 
levodopa dose was significantly associated with frailty status (r=0.61; p=0.01). However, we 
cannot be certain if dopaminergic dosage and frailty are directly associated, or if the observed 
relationship can likely be explained by disease severity affecting both frailty and drug dose. Two 
studies similarly noted that frail subjects had more advanced disease, quantified using the 
Hoehn and Yahr scale [12] or the Unified Parkinson’s Disease Rating Scale (UPDRS) [14].  
 
Associations between frailty, PD and outcomes 
 
One study examined other outcomes in a PD population, finding an association between worse 
quality of life scores and higher frailty (R2=0.12; p=0.02) as well as higher odds for frailty in 
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females (OR 9.8; CI 1.0-93.5)[12]. Frail subjects were also noted in one paper [10] to have lower 
scores on the Berg Balance Scale compared to non-frail individuals (20 vs 25.3; p=0.04). 
 
Discussion 
To the best of our knowledge, this is the first systematic review of frailty in Parkinson’s disease.  
Notably, whilst frailty and PD are both highly prevalent in older people, we only identified 8 
papers that had systematically and concurrently quantified these two conditions. 
Our main findings show that frailty is highly prevalent in individuals with PD, with the estimates 
of frailty prevalence we found lying above the average frailty expected in a non-PD population 
of similar age [19].   
The majority of studies operationalised frailty using the original or a modified version of the 
criteria proposed by Fried in the Cardiovascular Health Study, demonstrating that the criteria 
can be operationalised in people with PD. These criteria can be criticised from a reductionist 
perspective as simple outcomes that fail to recognise the complex psychosocial aspects of the 
frailty syndrome. Moreover, in the Cardiovascular Health Study, people with Parkinson’s were 
excluded [5]. Two of the Fried criteria form some of the recognised non-motor symptoms of 
Parkinson’s disease, namely fatigue and weight loss [20]. Since one of the other five Fried 
criteria, slow walking speed, is also a key feature of Parkinson’s disease, the Fried measure may 
actually risk overdiagnosing frailty in a PD population, by attributing their slow walking to frailty 
rather than their PD. Analysing these criteria as continuous variables rather than dichotomising 
them, as Ahmed et al. did in part [14], avoids loss of data.  
Alternatively, these Fried outcomes could be viewed as common endpoints arising from 
complex and varied underlying pathology. The more comprehensive approach advocated with 
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an index-based approach, as used in two papers [15,16], may better capture deficits in multiple 
domains and reflect the complexity of a frailty state.  Whilst the full index based approach may 
be difficult to operationalise in day-to-day clinical practice, the introduction of the visual Clinical 
Frailty Scale derived from the frailty index is validated for use in clinical settings [21] and offers 
scope to apply this to future cohorts. Critically, neither measure has been validated in a PD 
population with respect to predicting outcomes.  
Limitations of this review include the small number of papers included, which reflects the 
scarcity of research on this subject. Of note, one study also met our inclusion criteria but we 
were unable to extract data for our subsequent analysis, as it was not possible to gain 
information specific for PD subjects from the paper, and we were unsuccessful in obtaining the 
required information from the authors [18]. Small sample sizes may have resulted in a Type 2 
error whereby significant associations were incorrectly rejected, and we may have been 
underpowered to detect significant results. By including a spectrum of studies, from large 
population-based cohorts to smaller cross-sectional studies, we captured patients with 
different durations of PD. However, the heterogeneity of participant characteristics between 
different studies mean that the findings from studies of ambulant, independent PD subjects 
may not necessarily apply to those with more advanced disease. As well as significant variation 
in PD disease duration, differences in age and gender are likely to impact the frailty prevalence 
seen. We chose not to perform a meta-analysis of these studies, due to our acknowledgement 
that the heterogeneity of these papers and their limited number would impede an appropriate 
meta-regression analysis.  
 
PD and frailty are both conditions of older people.  Given the established association between 
frailty and vulnerability to negative clinical outcomes, recognition of these concurrent 
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conditions may help target modifiable factors that improve overall prognosis.  It remains to be 
delineated whether the two conditions share a pathophysiological basis and if so to what 
extent this shared aetiology can be targeted with intervention.  Future studies will need to 
delineate the strength of the association between disease factors, the presence of frailty and 
age on physical and psychosocial outcomes, and mortality.  However in current day-to-day 
clinical practice, recognition of frailty in those with PD should enhance targeting of treatment 
and, perhaps more importantly, discussion around future prognosis and care planning.  We 
propose that PD is an archetypal frailty syndrome and future research will improve recognition 
of the syndrome in this vulnerable population to better inform treatment decisions as well as 
prognosis.  
 
Key Points 
• This systematic review found 8 studies that had measured frailty in subjects with PD 
• Estimates of frailty prevalence lay between 29%-67% depending on frailty measure used 
• This emerging area warrants careful measurement in order to appropriately target 
interventions in this vulnerable population 
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Table 1: Characteristics of studies included in review. 
 Study Year Location Sampling 
frame 
Frailty 
measure 
N 
(total) 
N  
(PD) 
PD participants 
characteristics 
Mean age of 
PD group 
(SD) 
% female 
of PD 
group 
Frailty 
prevalence 
per 100 
(PD) 
Quality 
score  
/8  
Cross-sectional studies 
Roland10 2010-
2012 
Canada P Fried 13 13  H&Y I- III 
Mobile, cogn. 
intact 
67 (8) 100%  5 
Roland11 2012 Canada P Fried 30  
 
15  H&Y I –III 
Mobile, cogn.intact 
65 (9) 100%  5 
Roland12 2012 Canada P Fried 29 29  H&Y I-III  
mobile, cogn.intact 
66 (8.5) 41%  3 
Roland13 2011 Canada P Fried 35 17  H&Y I-III  
mobile, cogn.intact 
66 (8.5) 100% 29 5 
Ahmed14 2006 USA C Fried 49 49  Well-controlled PD, 
mobile 
70.8 (9.2) 33% 33 4 
Liotta15 2017 Italy P FGE 1331 18 Community-
dwelling 
76.3 (7.1)** 54%** 67 7 
Renne16 2018 Netherlands P TFI 241 6  Community-
dwelling 
79.3 (5.9) 17% 50 5 
Prospective cohort study 
Buchman17 1994-
2017 
USA P Fried* 2705 74 Mixed 85.2(6.4) 53% 32 8 
Table 1 
PD = Parkinson’s disease; SD = Standard deviation; Quality Score = Newcastle Ottawa Scale score; P=population; C=Clinical; Fried = California Health Study Frailty Index, (Fried 
criteria); *=adjusted version of Fried criteria; FGE = Functional Geriatric Evaluation questionnaire; TFI = Tilburg Frailty Indicator; H&Y = Hoehn & Yahr Scale; cogn intact = 
cognitively intact; **PD-specific age and gender information not provided, so age/gender figures used for overall sample 
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Figure 1: PRISMA flowchart of included studies 
Fig 1: PRISMA flowchart of included studies 
 
Figure 2: Forest Plot for prevalence of frailty in subjects with PD 
Fig 2: Forest plot of frailty prevalence by study. Studies displayed by mean participant age in 
ascending order 
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Supplementary Text S1: Search Strategy 
 
Pubmed search strategy: 
(((("parkinson disease"[MeSH Terms]) OR "parkinsonian disorders"[MeSH Terms]) OR parkinson*[Text 
Word])) AND frail*[Text Word] LIMIT English language 
 
Embase search strategy: 
‘Parkinson disease’/exp OR "parkinson*".ti,ab. AND ‘frail elderly’/exp OR "frail*".ti,ab. LIMIT to (human 
and english language) 
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Supplementary Table S2: Quality Assessment of all studies using Newcastle-Ottawa Scale 
Study [ref] Selection Comparability Outcome Total score 
CROSS-
SECTIONAL 
Representative 
(/1) 
Sample size 
(/1) 
PD dx 
(/1) 
Non response 
(/1) 
Control for key factors  
(/2) 
Frailty assessment 
(/1) 
Statistical test 
(/1) 
/8 
Roland [10]  * *  * * * 5 
Roland [11]   *  ** * * 5 
Roland [12]   *   * * 3 
Roland [13]   *  ** * * 5 
Ahmed [14] *  *   * * 4 
Liotta [15] * * * * * * * 7 
Renne [16] * *   **  * 5 
COHORT Representative 
(/1) 
Selection  
(/1) 
PD dx  
(/1) 
Control for key factors 
(/2) 
Frailty ax 
(/1) 
Follow up 
(/1) 
Loss to f/u 
(/1) 
/8 
Buchman [17] * * * ** * * * 8 
Table S2: Scoring matrix for studies: Studies’ methodologies scored according to the Newcastle Ottawa Scale.  
Points awarded for sample selection (including representativeness of sample, size, measurement of PD diagnosis and assessment of non-responders), 
comparability of outcome groups (control for confounding factors) and assessment of outcome (including frailty assessment, and in the case of cohort 
studies, adequacy of follow-up and assessment of loss to follow-up). Studies’ total scores listed, out of a possible maximum score of 8 points.  
  
